Haematology & Oncology News

S U P P O R T I N G A U S T R A L I A ’ S Quality Reliability Service

I V I g N E E D S

Introducing Flebogamma ® DIF IVIg to the Australian market

Concentration matters because every patient is different. Committed to appropriate use of Flebogamma ® DIF: available in 5% DIF or 10% DIF 1,2 Helping you choose the right concentration, at the lowest dosage, to meet each patient’s individual needs 3 Committed to delivery of Flebogamma ® DIF as a world leader in plasma collection 4 Our own vertically integrated supply of plasma helps ensure continuous production of Flebogamma ® DIF Committed to service To arrange a Flebogamma ® DIF in-service please call 1800 091 961 or email Australia_medinfo@grifols.com

Human Normal Immunoglobulin (IVIg)

References: 1. Flebogamma ® 5%DIF Product Information. January 2012. 2. Flebogamma ® 10%DIF Product Information. 12 February 2013. 3. National Blood Authority. Criteria for the clinical use of intravenous immunoglobulin in Australia. 2nd Edition, July 2012. 4. Data on file. Sponsored by: Grifols Australia Pty Ltd. Unit 5/80 Fairbank Road, Clayton South VIC 3169, Australia. Tel: +61 3 9535 9333. Fax: +61 3 9535 9300. Email: Australia_info@grifols.com. Date of preparation: March 2016. GRI0004/HON

Instituto Grifols, S.A. Can Guasc, 2 08150 Parets del Vallès, Barcelona – SPAIN Tel. (34) 935 710 100 www.grifols.com